- Home
- NAOV vs EDSA Comparison
NAOV vs EDSA Comparison
Compare NAOV & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAOV
- EDSA
- Stock Information
- Founded
- NAOV 2003
- EDSA 2015
- Country
- NAOV United States
- EDSA Canada
- Employees
- NAOV N/A
- EDSA N/A
- Industry
- NAOV Industrial Specialties
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- NAOV Health Care
- EDSA Health Care
- Exchange
- NAOV Nasdaq
- EDSA Nasdaq
- Market Cap
- NAOV 5.4M
- EDSA 6.2M
- IPO Year
- NAOV N/A
- EDSA N/A
- Fundamental
- Price
- NAOV $5.15
- EDSA $2.36
- Analyst Decision
- NAOV
- EDSA Strong Buy
- Analyst Count
- NAOV 0
- EDSA 1
- Target Price
- NAOV N/A
- EDSA $21.00
- AVG Volume (30 Days)
- NAOV 4.9M
- EDSA 8.9K
- Earning Date
- NAOV 05-14-2025
- EDSA 05-09-2025
- Dividend Yield
- NAOV N/A
- EDSA N/A
- EPS Growth
- NAOV N/A
- EDSA N/A
- EPS
- NAOV N/A
- EDSA N/A
- Revenue
- NAOV $2,558,000.00
- EDSA N/A
- Revenue This Year
- NAOV N/A
- EDSA N/A
- Revenue Next Year
- NAOV N/A
- EDSA N/A
- P/E Ratio
- NAOV N/A
- EDSA N/A
- Revenue Growth
- NAOV 12.05
- EDSA N/A
- 52 Week Low
- NAOV $1.92
- EDSA $1.55
- 52 Week High
- NAOV $16.25
- EDSA $5.59
- Technical
- Relative Strength Index (RSI)
- NAOV 48.45
- EDSA 51.83
- Support Level
- NAOV $5.86
- EDSA $2.29
- Resistance Level
- NAOV $6.24
- EDSA $2.40
- Average True Range (ATR)
- NAOV 1.58
- EDSA 0.12
- MACD
- NAOV -0.10
- EDSA 0.00
- Stochastic Oscillator
- NAOV 20.77
- EDSA 87.88
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.